Function of PNPLA3 I148M-Lessons From In Vivo Studies in Humans.

Area of Science:

• Hepatology
• Metabolic Syndrome Research
• Genetic Predisposition to Disease

Background:

• Steatotic liver disease (SLD) linked to insulin resistance (IR) and metabolic syndrome increases risks for liver, diabetes, and cardiovascular diseases (CVD).
• SLD associated with the PNPLA3 I148M variant also increases liver disease risk but offers protection against type 2 diabetes and CVD.
• The co-existence of these SLD types suggests differing pathogenic pathways despite overlapping clinical presentations.

Purpose of the Study:

• To compare the distinct effects of IR-SLD and PNPLA3-SLD on human health.
• To elucidate the differing molecular mechanisms underlying these two forms of SLD.
• To review human data on lipid metabolism, inflammation, and mitochondrial function in IR-SLD versus PNPLA3-SLD.

Main Methods:

• Review of human data comparing IR-SLD and PNPLA3-SLD.
• Analysis of effects on liver lipidome and fatty acid handling.
• Examination of triglyceride synthesis, circulating lipids, and adipose tissue inflammation.

Main Results:

• Comparison of liver lipidome, fatty acid metabolism, and triglyceride synthesis pathways.
• Assessment of circulating lipids, lipoproteins, and adipose tissue inflammation.
• Discussion of mitochondrial dysfunction in PNPLA3 I148M carriers with steatosis.

Conclusions:

• IR-SLD and PNPLA3-SLD exhibit distinct pathogenetic mechanisms.
• Understanding these differences is key to managing associated metabolic and liver diseases.
• Further research into mitochondrial function in PNPLA3-SLD is warranted.